After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

martin bonde gilead vaccibody

Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was Martin Bonde, CEO of Dansk Biotech and former CEO of Epitherapeutics which was sold at €60M to Gilead (the 2nd largest Biotech in the world). I just read he is switching to Vaccibody the Norwegian Biotech and I wanted to share his profile with you.

First, here is a video of him describing the Danish Biotech ecosystem:

After being CEO of six different Biotechs, he is now jumping into a new challenge by joining Vaccibody. It is an immunotherapy and vaccine company targeting cancer and infectious diseases. Its lead program is a therapeutic DNA vaccine against Human Papiloma Virus.

Martin will bring his extensive experience to the field to take Vaccibody to the next level and maybe sign a big deal, as he is used to do.

Update 10.07.2015: Vaccibody is based in Oslo, Norway and not in Finland.

Previous post

CEVEC and Biotest to ease hemophilia patients’ lifes

Next post

Kiadis launches its Cell-based Immunotherapies on European stock markets

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.